EMA recommends 10 medicines for approval in October meeting
Ten medicines have been recommended for marketing authorisation and 10 extensions of indication have been suggested by the EMA.
List view / Grid view
Ten medicines have been recommended for marketing authorisation and 10 extensions of indication have been suggested by the EMA.
The European Investment Bank (EIB) will provide Immunic with up to €24.5 million to support the ongoing development of IMU-838, a potential COVID-19 therapy.
The UK government hopes to expedite the development of a COVID-19 vaccine by investing £33.6 million in the first phase of establishing human challenge trials.
Researchers have developed a monoclonal antibody called AR-711 that is highly neutralising against COVID-19 in an inhaled formulation.
WHO has said that remdesivir, hydroxychloroquine, lopinavir/ritonavir and interferon had little or no effect when treating hospitalised patients with COVID-19.
A new report has predicted that the COVID-19 pandemic will drive demand for pharmaceutical spray drying, boosting the market.
Researchers comparing dolutegravir to efavirenz suggest dolutegravir increases viral suppression and has similar rates of adverse events.
The FDA is requiring that the prescribing information for nonsteroidal anti-inflammatory drugs (NSAIDs) include warnings about potential foetal kidney problems if taken by women over 20 weeks pregnant.
Specialised in aseptic and containment barrier Isolation technology systems, Telstar UK has seen increased demand for its products from all across the life sciences sector has grown significantly in the past few years.
A report found the rise in outsourcing, growing popularity of biologics and expanding acceptance of quality-by-design approaches would drive the market expansion.
16 October 2020 | By
The Chinese COVID-19 vaccine candidate BBIBP-CorV elicited an antibody response in all recipients, according to preliminary Phase I/II trial data.
By joining the Access Consortium, the MHRA will work together with agencies from Australia, Canada, Singapore and Switzerland to expedite therapeutic product approvals.
The adaptive ACTIV-5/BET study will test two monoclonal antibody therapies in hospitalised COVID-19 patients to establish if they warrant larger clinical trials.
The US Food and Drug Administration (FDA) has approved Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) for the treatment of Zaire ebolavirus infection in adults and children.
A Phase I clinical trial to test VXA-CoV2-1, an oral tablet COVID-19 vaccine candidate, has been initiated with the first patient dosed.